| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
The angiogenic factor PD-ECGF/TP is expressed at high levels in a variety of solid tumors compared with normal tissue. In this study, we aimed at the development of radiopharmaceuticals for imaging of angiogenesis. To develop a radioprobe for angiogenesis imaging, a radiolabeled uracil-based PD-ECGF/TP inhibitor, BOMU and IIMU were designed and radiosynthesized. These radiolabeled uracil derivatives showed high and specific accumulation of in PD-ECGF/TP-expressing tumors. These finding indicate that radiolabeled uracil deserves further evaluation as a novel single photon emission computed tomography (SPECT) probe for imaging of tumor angiogenesis.
|
